Ocrelizumab vs Ublituximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
Ocrelizumab
Marketed by Roche
NCT00676715 · Phase 2 · completed
Randomized, double-blind phase 2 in relapsing-remitting multiple sclerosis (220 participants). Both ocrelizumab doses reduced gadolinium-enhancing brain lesions decisively versus placebo (p<0.0001); the endpoint is an MRI biomarker rather than a clinical relapse or disability outcome, which is why the grade is moderate despite the clear result.
Next expected readout: December 2026 · NCT04466150 (registry estimate)
Reported efficacy
Protocol-defined Annualized Relapse Rate (ARR) (Up to after the last participant randomized completed 24 weeks since first study treatment administration (up to approximately 160 weeks)): Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk. (met)
Result source: NCT05123703
Ublituximab · Briumvi
Marketed by TG THERAPEUTICS, INC. and partners
NCT03277261 · Phase 3 · completed
This was a randomized, quadruple-masked, active-controlled trial of 549 participants, with ublituximab and teriflunomide administered alongside matching placebos. The primary clinical endpoint was met: ublituximab produced a significantly lower annualized relapse rate than teriflunomide through 96 weeks (p<0.0001).
Next expected readout: January 2027 · NCT05877963 (registry estimate)
Reported efficacy
Annualized Relapse Rate (ARR) (Up to 96 weeks): Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291) (met)
Result source: NCT03277248
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ocrelizumab | Ublituximab |
|---|---|---|
| Annualised relapse rate | 0.2 vs 0.3vs Interferon Beta-1aNCT012473243 other results
| 0.1 vs 0.2vs TeriflunomideNCT032772611 other result
|
| Free of 3-month confirmed disability progression (%) | —Trial running · NCT05834855 | —Trial running · NCT07220252 |
| New or enlarging T2 lesions | 430 vs 1916vs Interferon Beta-1aNCT012473241 other result
| —Trial running · NCT07220252 |
Annualised relapse rate
- Ocrelizumab
- 0.2 vs 0.3vs Interferon Beta-1aNCT01247324
3 other results
- 0.2 vs 0.3 NCT01412333
- 0.1 vs 0.6 NCT00676715
- 0.2 vs 0.6 NCT00676715
- Ublituximab
- 0.1 vs 0.2vs TeriflunomideNCT03277261
1 other result
- 0.1 vs 0.2 NCT03277248
Free of 3-month confirmed disability progression (%)
- Ocrelizumab
- —Trial running · NCT05834855
- Ublituximab
- —Trial running · NCT07220252
New or enlarging T2 lesions
- Ocrelizumab
- 430 vs 1916vs Interferon Beta-1aNCT01247324
1 other result
- 380 vs 2103 NCT01412333
- Ublituximab
- —Trial running · NCT07220252
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Ocrelizumab: 7 of 7 rows · Ublituximab: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ocrelizumab Rows use multiple source trials | Ublituximab Rows use multiple source trials |
|---|---|---|
| Annualized Relapse event rate · per year No placebo or comparator arm | 0.03 per year @ 96wka,b,c,d NCT02861014 · Phase 3 · registry result, not featured evidence 1 other source trial0.046 per year @ 96wk NCT02637856 · Phase 3 · registry result, not featured evidence | 0.28 per year @ 48wke,a,b,c,d NCT02738775 · Phase 2 · registry result, not featured evidence show 5 more doses0 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0.14 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0.14 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence |
| Brain Volume percent change · % of baseline | -0.572% (n=281) vs -0.741% (n=267) Interferon Beta-1a @ 96wkb,c NCT01247324 · Phase 3 1 other source trial-0.638% (n=287) vs -0.75% (n=259) Interferon Beta-1a @ 96wk NCT01412333 · Phase 3 · registry result, not featured evidence | -0.197% (n=204) vs -0.125% (n=207) Teriflunomide @ 96wkb,c NCT03277261 · Phase 3 · combination 1 other source trial-0.194% (n=235) vs -0.176% (n=224) Teriflunomide @ 96wk NCT03277248 · Phase 3 · combination |
| NEDA responder rate · % of participants | 47.4% (n=289) vs 27.1% (n=291) Interferon Beta-1a @ 96wkb,c NCT01247324 · Phase 3 1 other source trial43.9% (n=289) vs 24.1% (n=270) Interferon Beta-1a @ 96wk NCT01412333 · Phase 3 · registry result, not featured evidence | 44.6% (n=271) vs 15% (n=274) Teriflunomide @ 96wkb,c NCT03277261 · Phase 3 · combination 1 other source trial43% (n=272) vs 11.4% (n=272) Teriflunomide @ 96wk NCT03277248 · Phase 3 · combination |
| Dropout rate | 16.4%600 mg / 600 mgf NCT00676715 · Phase 2 show 25 more results—600 mg NCT00676715 · Phase 2 —600 mg / 600 mg NCT00676715 · Phase 2 21.8%1000 mg / 600 mg NCT00676715 · Phase 2 —1000 mg / 600 mg NCT00676715 · Phase 2 55.3%600 mg NCT01194570 · Phase 3 —DB OCRELIZUMAB NCT01194570 · Phase 3 —OLE OCRELIZUMAB NCT01194570 · Phase 3 —OLE PLACEBO NCT01194570 · Phase 3 41.7%Ocrelizumab NCT01247324 · Phase 3 —Ocrelizumab + Placebo (Double Blin NCT01247324 · Phase 3 —Ocrelizumab + Placebo (Open Label NCT01247324 · Phase 3 7.7% NCT04998851 · Phase 4 · registry result, not featured evidence 0% NCT04261790 · Phase 4 · registry result, not featured evidence 10% NCT03853746 · Phase 4 · registry result, not featured evidence 96.8%PPMS Cohort: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 100%RMS Cohort Arm 1: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 100%RMS Cohort Arm 2: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 100%RMS Cohort Arm 3: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 100%RMS Cohort Arm 4: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination —Ocrelizumab + Interferon Beta-1a P NCT01412333 · Phase 3 · registry result, not featured evidence · combination —Ocrelizumab + Interferon Beta-1a P NCT01412333 · Phase 3 · registry result, not featured evidence · combination 5.7% NCT02861014 · Phase 3 · registry result, not featured evidence 36%Ocrelizumab NCT02637856 · Phase 3 · registry result, not featured evidence —Ocrelizumab (Substudy) NCT02637856 · Phase 3 · registry result, not featured evidence 7% NCT02980042 · Phase 3 · registry result, not featured evidence | 12.4%f NCT03277261 · Phase 3 · combination show 7 more results6.6% NCT03277248 · Phase 3 · combination 0%Cohort 1 NCT02738775 · Phase 2 · registry result, not featured evidence 25%Cohort 2 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 3 NCT02738775 · Phase 2 · registry result, not featured evidence 11.1%Cohort 4 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 5 NCT02738775 · Phase 2 · registry result, not featured evidence 12.5%Cohort 6 NCT02738775 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 5.5%600 mg / 600 mgf NCT00676715 · Phase 2 show 25 more results—600 mg NCT00676715 · Phase 2 —600 mg / 600 mg NCT00676715 · Phase 2 3.6%1000 mg / 600 mg NCT00676715 · Phase 2 —1000 mg / 600 mg NCT00676715 · Phase 2 8.2%600 mg NCT01194570 · Phase 3 —DB OCRELIZUMAB NCT01194570 · Phase 3 —OLE OCRELIZUMAB NCT01194570 · Phase 3 —OLE PLACEBO NCT01194570 · Phase 3 8.5%Ocrelizumab NCT01247324 · Phase 3 —Ocrelizumab + Placebo (Double Blin NCT01247324 · Phase 3 —Ocrelizumab + Placebo (Open Label NCT01247324 · Phase 3 — NCT04998851 · Phase 4 · registry result, not featured evidence — NCT04261790 · Phase 4 · registry result, not featured evidence — NCT03853746 · Phase 4 · registry result, not featured evidence 0%PPMS Cohort: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 4.3%RMS Cohort Arm 1: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 6.5%RMS Cohort Arm 2: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 7.1%RMS Cohort Arm 3: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 0%RMS Cohort Arm 4: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination —Ocrelizumab + Interferon Beta-1a P NCT01412333 · Phase 3 · registry result, not featured evidence · combination —Ocrelizumab + Interferon Beta-1a P NCT01412333 · Phase 3 · registry result, not featured evidence · combination 1% NCT02861014 · Phase 3 · registry result, not featured evidence 1.5%Ocrelizumab NCT02637856 · Phase 3 · registry result, not featured evidence —Ocrelizumab (Substudy) NCT02637856 · Phase 3 · registry result, not featured evidence — NCT02980042 · Phase 3 · registry result, not featured evidence | 6.2%f NCT03277261 · Phase 3 · combination show 7 more results1.1% NCT03277248 · Phase 3 · combination 0%Cohort 1 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 2 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 3 NCT02738775 · Phase 2 · registry result, not featured evidence 11.1%Cohort 4 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 5 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 6 NCT02738775 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —600 mg / 600 mgf NCT00676715 · Phase 2 show 25 more results27.2%600 mg NCT00676715 · Phase 2 30.9%600 mg / 600 mg NCT00676715 · Phase 2 —1000 mg / 600 mg NCT00676715 · Phase 2 29.1%1000 mg / 600 mg NCT00676715 · Phase 2 —600 mg NCT01194570 · Phase 3 21.4%DB OCRELIZUMAB NCT01194570 · Phase 3 45.3%OLE OCRELIZUMAB NCT01194570 · Phase 3 37.3%OLE PLACEBO NCT01194570 · Phase 3 —Ocrelizumab NCT01247324 · Phase 3 6.9%Ocrelizumab + Placebo (Double Blin NCT01247324 · Phase 3 33%Ocrelizumab + Placebo (Open Label NCT01247324 · Phase 3 0% NCT04998851 · Phase 4 · registry result, not featured evidence 0% NCT04261790 · Phase 4 · registry result, not featured evidence 0% NCT03853746 · Phase 4 · registry result, not featured evidence 29%PPMS Cohort: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 21.7%RMS Cohort Arm 1: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 16.1%RMS Cohort Arm 2: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 3.6%RMS Cohort Arm 3: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 27.8%RMS Cohort Arm 4: Ocrelizumab + LP NCT02688985 · Phase 3 · registry result, not featured evidence · combination 7%Ocrelizumab + Interferon Beta-1a P NCT01412333 · Phase 3 · registry result, not featured evidence · combination 34.6%Ocrelizumab + Interferon Beta-1a P NCT01412333 · Phase 3 · registry result, not featured evidence · combination 7.2% NCT02861014 · Phase 3 · registry result, not featured evidence 7.7%Ocrelizumab NCT02637856 · Phase 3 · registry result, not featured evidence 1.6%Ocrelizumab (Substudy) NCT02637856 · Phase 3 · registry result, not featured evidence 8% NCT02980042 · Phase 3 · registry result, not featured evidence | 11.4%f NCT03277261 · Phase 3 · combination show 7 more results10.3% NCT03277248 · Phase 3 · combination 0%Cohort 1 NCT02738775 · Phase 2 · registry result, not featured evidence 12.5%Cohort 2 NCT02738775 · Phase 2 · registry result, not featured evidence 25%Cohort 3 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 4 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 5 NCT02738775 · Phase 2 · registry result, not featured evidence 25%Cohort 6 NCT02738775 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 600 mgf multiple sclerosis relapse 27.2% (placebo 48.1%) covid-19 25.2% (placebo 22.2%) infusion related reaction 22.3% (placebo 53.7%) NCT00676715 · Phase 2 show 21 more results600 mg / 600 mg infusion related reaction 45.5% (placebo 53.7%) multiple sclerosis relapse 34.5% (placebo 48.1%) nasopharyngitis 27.3% (placebo 18.5%) NCT00676715 · Phase 2 1000 mg / 600 mg infusion related reaction 52.7% (placebo 53.7%) multiple sclerosis relapse 38.2% (placebo 48.1%) urinary tract infection 27.3% (placebo 25.9%) NCT00676715 · Phase 2 infusion related reaction 39.9% (placebo 25.5%) nasopharyngitis 24.1% (placebo 26.4%) urinary tract infection 21.2% (placebo 23.8%) NCT01194570 · Phase 3 urinary tract infection 34.4% (placebo 23.8%) nasopharyngitis 27.1% (placebo 26.4%) covid-19 20.6% (placebo 0%) NCT01194570 · Phase 3 nasopharyngitis 30.4% (placebo 26.4%) urinary tract infection 27.8% (placebo 23.8%) infusion related reaction 25.3% (placebo 25.5%) NCT01194570 · Phase 3 infusion related reaction 30.9% upper respiratory tract infection 14.5% urinary tract infection 12.7% NCT01247324 · Phase 3 urinary tract infection 28.7% covid-19 27.3% upper respiratory tract infection 25.6% NCT01247324 · Phase 3 covid-19 46.2% infusion related reaction 23.1% nasopharyngitis 23.1% NCT04998851 · Phase 4 · registry result, not featured evidence headache 30% cough 20% blood pressure fluctuation 10% NCT04261790 · Phase 4 · registry result, not featured evidence bronchitis 11.1% congestion 11.1% cough 11.1% NCT03853746 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 41.9% infusion related reaction 38.7% arthralgia 35.5% NCT02688985 · Phase 3 · registry result, not featured evidence · combination infusion related reaction 65.2% upper respiratory tract infection 30.4% covid-19 17.4% NCT02688985 · Phase 3 · registry result, not featured evidence · combination sinusitis 32.3% infusion related reaction 29% headache 19.4% NCT02688985 · Phase 3 · registry result, not featured evidence · combination infusion related reaction 57.1% upper respiratory tract infection 35.7% pain in extremity 17.9% NCT02688985 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 66.7% infusion related reaction 61.1% urinary tract infection 38.9% NCT02688985 · Phase 3 · registry result, not featured evidence · combination infusion related reaction 37.9% nasopharyngitis 19.2% upper respiratory tract infection 15.6% NCT01412333 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 30.6% covid-19 27.4% nasopharyngitis 27.4% NCT01412333 · Phase 3 · registry result, not featured evidence · combination infusion related reaction 43.2% nasopharyngitis 30.9% headache 22.6% NCT02861014 · Phase 3 · registry result, not featured evidence infusion related reaction 43.3% urinary tract infection 14.5% nasopharyngitis 10.5% NCT02637856 · Phase 3 · registry result, not featured evidence infusion related reaction 12.4% fatigue 0% headache 0% NCT02637856 · Phase 3 · registry result, not featured evidence upper respiratory infection 36% headache 14% nausea 14% NCT02980042 · Phase 3 · registry result, not featured evidence | show 7 more resultsback pain 37.5% (placebo 0%) headache 25% (placebo 15.4%) hypoaesthesia 25% (placebo 7.7%) NCT02738775 · Phase 2 · registry result, not featured evidence dizziness 37.5% (placebo 23.1%) fatigue 37.5% (placebo 38.5%) headache 37.5% (placebo 15.4%) NCT02738775 · Phase 2 · registry result, not featured evidence arthralgia 25% (placebo 7.7%) diarrhoea 25% (placebo 0%) fatigue 25% (placebo 38.5%) NCT02738775 · Phase 2 · registry result, not featured evidence fatigue 50% (placebo 38.5%) nasopharyngitis 37.5% (placebo 0%) sinusitis 37.5% (placebo 15.4%) NCT02738775 · Phase 2 · registry result, not featured evidence dysphagia 37.5% (placebo 15.4%) infusion related reaction 37.5% (placebo 23.1%) throat irritation 37.5% (placebo 15.4%) NCT02738775 · Phase 2 · registry result, not featured evidence nausea 62.5% (placebo 15.4%) dizziness 37.5% (placebo 23.1%) fatigue 37.5% (placebo 38.5%) NCT02738775 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 96 weeks versus 48 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ocrelizumab
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 1 more result
+ 38 further endpoints in the CSV export.
Ublituximab
show 1 more result
show 1 more result
show 1 more result
show 11 more results
show 11 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ocrelizumab's landscape · Ublituximab's landscape